Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Ammoxetine Hydrochloride in Hepatic Impairment
NCT07694843Phase 1Recruiting
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Mar 2026
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of ammoxetine in major depressive disorder (MDD) (3 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Area under the concentration vs. time curve for one dosing interval at steady-state and Maximum concentration observed during dosing interval at steady-state. Started Mar 2026; status: recruiting.
02
Drugs
ammoxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07694843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07694843.